New Agent Overcomes Drug Resistance in HER2-Positive Breast Cancer, Preclinical Study Shows (Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center)

A type of breast cancer that often develops resistance to targeted therapies was driven back into remission in mice by a drug that blocks the division of cancer cells, a new study led by researchers at Dana-Farber Cancer Institute has found. The results, reported in Cancer Cell, prompted investigators to launch a clinical trial of the new agent in women with a metastatic form of this cancer, known as HER2-positive breast cancer. Dana-Farber/Brigham and Women's Cancer Center | Massachusetts Ge...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news